Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer

- Bing Zeng^{1,2}, Peide Huang², Peina Du³, Xiaohui Sun³, Xuanlin Huang², Xiaodong Fang^{1,2,4*}, Lin
 Li^{2*}
- ⁵ ¹ BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, 518083, China
- 6 ² BGI-Shenzhen, Shenzhen, 518083, China
- ³ BGI Genomics, BGI-Shenzhen, Shenzhen, 518083, China
- ⁴ China National GeneBank, BGI-Shenzhen, Shenzhen 518120, China
- 9 *** Correspondence:**
- 10 Lin Li
- 11 Email: <u>lilin_contact@163.com</u>
- 12 <u>Xiaodong Fang</u>
- 13 Email: <u>fangxd@bgi.com</u>
- Keywords: Esophageal squamous cell cancer, cancer susceptibility gene, double-hit, germline
 mutation, pathogenicity
- 16
- 17 Abstract
- 18 Esophageal squamous cell cancer (ESCC) is the eighth most common cancer around the world.
- 19 Several reports have focused on somatic mutations and common germline mutations in ESCC.
- 20 However, the contributions of pathogenic germline alterations in cancer susceptibility genes (CSGs),
- 21 highly frequently mutated CSGs, and pathogenically mutated CSG-related pathways in ESCC remain
- 22 unclear. We obtained data on 571 ESCC cases from public databases and East Asian from the 1000
- 23 Genomes Project database and the China Metabolic Analytics Project database to characterize
- 24 pathogenic mutations. We detected 157 mutations in 75 CSGs, accounting for 25.0% (143/571) of
- ESCC cases. Six genes had more than five mutations: TP53 (n = 15 mutations), GJB2 (n = 8), BRCA2 (n = 6), RECOL4 (n = 6), MUTYH (n = 6), and PMS2 (n = 5). Our results identified
- BRCA2 (II = 6), RECQL4 (II = 6), MOTTH (II = 6), and PMS2 (II = 5). Our results identified significant differences in pathogenic germline mutations of TP53, BRCA2, and RECQL4 between the
- ESCC and control cohorts. Moreover, we identified 84 double-hit events (16 germline/somatic
- 29 double-hit events and 68 somatic/somatic double-hit events) occurring in 18 tumor suppressor genes
- 30 from 83 patients. Patients who had ESCC with germline/somatic double-hit events were diagnosed at
- 31 younger ages than patients with the somatic/somatic double-hit events, although the correlation was
- 32 not significant. Fanconi anemia was the most enriched pathway of pathogenically mutated CSGs, and
- it appeared to be a primary pathway for ESCC predisposition. The results of this study identified the
- 34 underlying roles that pathogenic germline mutations in CSGs play in ESCC pathogenesis; increased
- 35 our awareness about the genetic basis of ESCC; and provided suggestions for using highly mutated
- 36 CSGs and double-hit features in the early discovery, prevention, and genetic counseling of ESCC.

37 1 Introduction

38 Esophageal squamous cell cancer (ESCC) is one of the most common cancers in the world, and it is

39 especially common in Asian countries, North America, and the eastern corridor of Africa (1). In

40 China, there are approximately 478,000 new cases and 375,000 deaths related to ESCC each year (2).

41 Many factors reportedly have relationships with ESCC; these include smoking, drinking, and dietary 42 habits (3). However, the hereditary factors involved in ESCC remain unclear. Thus, understanding

habits (3). However, the hereditary factors involved in ESCC remain unclear. Thus, understanding
 the genetic mutations and molecular events in ESCC might be pivotal to reduce the incidence and

- 44 mortality rate of ESCC.
- 45 Enormous efforts have been taken to identify somatic alterations by whole-genome sequencing
- 46 (WGS) or whole-exome sequencing (WES) (4,5), and several studies reveal the complex process of
- 47 tumor development (6,7). Many common germline single-nucleotide polymorphisms (SNPs) have
- 48 been identified by genome-wide association studies (8–16). rs138478634, a *CYP26B1* low-frequency
- 49 variant, was proved to be involved in ESCC development (14). In 2018, several pan-cancer studies
- 50 focused on pathogenic germline mutations to explore hereditary factors in cancers; 871 rare cancer
- 51 predisposition mutations and copy number variations (CNVs) were observed in 8% of 10,389 cases,
- 52 and 7.6% of the 914 patients with pediatric cancers had tumors that harbored pathogenic mutations in
- 53 cancer predisposition genes (17,18). Deng et al. (19) identified germline profiles in Chinese patients
- 54 with ESCC and uncovered the association between genotype and environment interactions.
- Additionally, *BRCA2* was associated with ESCC risk in Chinese patients (20). Reflecting a critical
- 56 part of cancer susceptibility, the two-hit hypothesis assumes that hereditary retinoblastoma involves
- 57 double mutations and that one mutation is in germline DNA whereas nonhereditary retinoblastoma
- 58 involves two somatic mutations (21). On the basis of these findings, double-hit events in some 59 studies were used to identify cancer predisposition genes (22,23). These studies demonstrated the
- 59 studies were used to identify cancer predisposition genes (22,23). These studies demonstrated the 60 significance of pathogenic germline mutations and double-hit events in genetic testing and risk
- 60 significance of pathogenic germline mutations and double-hit events in ger 61 assessment for cancer.
- 62 To our knowledge, cancer predisposition genes and molecular events in ESCC remain poorly

63 understood. Here, we identified pathogenic/likely pathogenic germline predisposition mutations and

64 highly frequently mutated CSGs in a large ESCC cohort. We discovered significantly different

- 65 pathogenic germline mutations of *TP53*, *BRCA2*, and *RECQL4* in ESCC cohorts, and we clarified the
- association between double-hit events and diagnosis age in patients with ESCC. In addition, we
- 67 identified pathogenically mutated CSG-related pathways for ESCC to illuminate the mechanism
- affected by pathogenic mutations. Results of this study will improve genetic testing for relatives of
- 69 patients with ESCC and facilitate implementation of organizational or institutional measures for
- 70 ESCC prevention and surveillance.

71 2 Materials and Methods

72 2.1 Sample acquisition

73 We collected 592 ESCC samples from published studies and The Cancer Genome Atlas (a total of

nine projects) (Supplementary Table 1), and we excluded poor-quality samples and hypermutant

samples (4,5,24–29). Clinical information is listed in Supplementary Table 2. The WGS and WES

76 data from the same studies came from distinct patient cases. The quality control analysis uncovered

an average sequencing depth of $55 \times 161 \times$ for WES samples and $30 \times 65 \times$ for WGS samples

- 78 (Supplementary Figure 1A), the $10 \times$ average coverages were more than 90% in most WES and WGS
- samples (Supplementary Figure 1B). Moreover, the relationship between 10× average coverages and
- 80 average sequencing depths showed a positive correlation (Supplementary Figure 1C), suggesting that

- 81 the qualities of most samples were proofed. The mean depth of our data and the public databases we
- 82 used as controls were able to provide enough variants to execute downstream analysis (30). The
- 83 study protocol was reviewed by the institutional review board of the Beijing Genomics Institution.

84 2.2 Data processing and mutation calling

- The fastq data from 571 samples (38 WGS samples, 533 WES samples) were trimmed and filtered
- using SOAPnuke (v1.5.6 with default parameters, except where -n 0.1 -l 11 -q 0.5 -G -T 1) (31). Data
- 87 from ESCC-P006 was transformed from bam files using the GATK SamToFastq (v4.0.6.0 with
- default parameters) (32). The high-quality reads were aligned to the hg19 human reference genome
- 89 with a Burrows-Wheeler Aligner (v0.7.17-r1194-dirty with default parameters, except where -o 1 -e
- 50 -m 100000 -i 15 -q 10 -a 600) (33). MarkDuplicates GATK (version as above with default
- 91 parameters, except where -CREATE_INDEX true, -reportMemoryStats true, -
- 92 VALIDATION_STRINGENCY SILENT) was used to mark duplicated reads. BaseRecalibrator
- 93 (version as above with default parameters) and ApplyBQSR (version as above with default
- 94 parameters, except where -create-output-bam-index true) were performed to base quality score
- 95 recalibration (32). Germline variants were joint-called using GenotypeGVCFs (version as above with
- 96 default parameters, except where -ignore-variants-starting-outside-interval true) after
- 97 CombineGVCFs (version as above with default parameters) and annotated with the Variant Effect
- 98 Predictor (VEP v98.3) (32,34). The calling germline variants of nine projects are shown in
- 99 Supplementary Figure 1D. Samples with fewer than 80,000 variants were filtered out. Somatic
- 100 variants were detected by GATK MuTect2 (version as above with default parameters except where -
- 101 af-of-alleles-not-in-resource 0.0000025, -native-pair-hmm-threads 1, -add-output-vcf-command-line
- 102 false), and Oncotator (v1.9.9.0) was used for annotation (32,35). Loss of heterozygosity (LOH) and
- 103 other somatic CNVs (SCNVs) were detected with FACETS (v0.5.14) and Pathwork (v1.0) for 533
- 104 WES and 38 WGS samples, respectively (36,37).

105 **2.3** CSG sets

- 106 We curated CSGs from published papers and the Catalogue of Somatic Mutations in Cancer
- 107 (COSMIC) database (38); we included cancer predisposition genes from three papers (17,18,39) and
- 108 genes with recorded germline associations in COSMIC (Supplementary Table 4). After we removed
- 109 duplicated genes, the CSG set included 260 genes. CSGs were divided into three groups according to
- 110 the literature (17,40–42); these groups were tumor suppressor genes (TSGs; n = 139), oncogenes (n = 139)
- 111 36), and nonclassified genes (n = 85).

112 **2.4 Pathogenicity evaluation**

- 113 We first leveraged an in-house pathogenicity database to match germline variants; the rest of the
- germline variants were evaluated using InterVar (InterVar_20190327) as a supplemental method to
- find germline pathogenic/likely pathogenic mutations (43). Germline pathogenic or likely pathogenic variants are hereafter referred to as pathogenic mutations. The pathogenicity database included
- variants are hereafter referred to as pathogenic mutations. The pathogenicity database included
 ClinVar, the Human Gene Mutation Database, mutations collected from papers, and mutations we
- assessed according to consensus guidelines by the American College of Medical Genetics and
- 119 Genomics and the Association for Molecular Pathology (17,44–46). We filtered for pathogenic
- variants with an allele frequency of 0.5% or lower in the Genome Aggregation Database (gnomAD
- version v2.1) (47). Pathogenic mutations in 260 high-interest CSGs (Supplementary Table 6) were
- selected for analysis and were checked by Deep Variant (48); manual verification ruled out false-
- positive results. For somatic nonsilent variants, with the exception of frameshift, nonsense, and
- 124 splice-site mutations, three silico tools—SIFT (49), Polyphen2_HDIV (50) and CADD (51) were

used to predict pathogenicity. If a variant was predicted as damaging in any two silico tools (SIFT:

126 D, Polyphen2_HDIV: D/P, CADD score > 15), the variant was categorized as deleterious (39,52).

127 **2.5** Identification of potential double-hit events

128 According to the two-hit hypothesis, potential double-hit events are identified after two or more hits

- have been found in the same CSG; in this study, we set rigorous standards for determining hits.
- 130 Pathogenic germline mutations were considered hits. Effective somatic variations were defined as
- 131 hits if they met the following requirements: frameshift, nonsense, splice-site mutations, or deleterious
- missense and in-frame variants and SCNVs that caused allele loss. Copy-neutral LOH, duplication
- 133 LOH, homozygous deletion, and hemizygous deletion were assumed to be linked to allele loss and
- were termed allele loss SCNVs (53,54). Integrative Genomics Viewer software was used to examine
 the authenticity of biallelic events (55). For double-hit events comprised of germline hits and allele
- 136 loss SCNVs, we calculated SNP average depths and variant allelic frequency in normal and tumor
- tissues of ESCC to further validate allele loss SCNV events. Samples with variant allele frequencies
- 138 less than 0.5 in tumors were removed.

139 2.6 Statistical analyses

- 140 To evaluate the correlations of the clinical features and genetic events, we used the two-sided
- 141 Student's t-test. We conducted the two-sided Fisher's exact test to assess the gene-based association
- 142 analysis and pathway enrichment. We also performed a burden test to determine the exact
- 143 relationships between pathogenic mutations in CSGs and ESCC (56); p < 0.05 was defined as
- 144 statistically significant.

145 **3 Results**

146 **3.1 Population characteristics**

- 147 Overall, 469 of 571 patient cases were Asian (424 Chinese, 41 Vietnamese, one Canadian, one
- 148 Brazilian, two without country information), 41 were Caucasian, 58 were Black or African American,
- and the rest were Brazilian without ethnicity information. The entire population consisted of 105
- women, 465 men, and one patient without gender information. The average diagnosed age for 567
- patients (the rest had no information) was 58.81 years (the minimum diagnosed age was 24 years,
- and the maximum diagnosed age was 93 years). Thirty-five patients had family histories of ESCC, and the average age of patients with ESCC with a family histories of ESCC.
- and the average age of patients with ESCC with a family history (mean age and standard deviation [SD] was 56.80 [9.3] years; [range, 41–82 years]). This average was lower than the age of patients
- [SD] was 56.80 [9.3] years; [range, 41–82 years]). This average was lower than the age of patients
 with ESCC without a family history (mean age [SD], 60.00 [8.2] years; [range, 36–78 years]; t-test *p*
- = 0.059; 95% CI, -6.511 to 0.121) (Supplementary Figure 2). The average survival for 399 patients
- 157 (the rest had no information) was 879.8 days (minimum survival, 3 days; maximum survival, 2,580
- days). In this study, 347 patients had a smoking history, and 215 patients had histories of alcoholism.
- 159 With regard to disease grade, 334 patients had disease with pathological grade 2 or lower, and 86
- 160 patients had disease with pathological grade greater than 2; pathological grade information was
- 161 missing for 151 patients. All patients were diagnosed with disease stages I (n = 72), stage II (n =
- 162 207), stage III (n = 203), and stage IV (n = 7); 82 patients were not assigned disease stages for this
- 163 study (their information was lost).
- 164 [Insert Figure 1 here]

165 **3.2 Pathogenic germline mutations in CSGs**

- 166 Overall, 2,484 pathogenic germline mutations were identified, including 1,973 SNPs and 511
- 167 insertions or deletions (Supplementary Table 5). Each sample had an average of 4.4 pathogenic
- 168 mutations. After filtration by CSGs, 157 pathogenic mutations (113 SNPs and 44 insertions or
- deletions) were discovered from 25.0% (143/571) of the population (Supplementary Figure 3).
- 170 Although each sample had an average of 1.1 pathogenic mutation in CSGs, only 12 (2.10%) of the
- 171 571 patients harbored one or more pathogenic mutation in CSGs (Figure 1, Supplementary Table 6).
- 172 The frequency of most mutations was rare in the gnomAD noncancer database and in the China
- 173 Metabolic Analytics Project (ChinaMAP) database (47,57), indicating the sparsity of these
- 174 deleterious mutations in the general population. As expected, most of the frequently mutated CSGs
- belonged to TSGs, and they were involved in biological processes, such as DNA repair.
- 176 In general, the CSGs detected more than five times were TP53 (n = 15 mutations), GJB2 (n = 8),
- 177 BRCA2 (n = 6), RECQL4 (n = 6), MUTYH (n = 6), and PMS2 (n = 5). TP53 was the most frequently
- 178 mutated CSG, with pathogenic germline mutations in 2.63% (15/571) of patients with ESCC (Figure
- 179 1, Supplementary Table 6 and Supplementary Figure 4); The result was the same as *TP53* pathogenic
- 180 mutations in a study of osteosarcoma (39). In our study, 86.7% (13/15) of *TP53* mutations were
- 181 nonsynonymous single-nucleotide variations. c.A1073T (rs773553186; in 0.35%, or 2/571) and
- 182 c.C742T (rs121912851; in 0.18%, or 1/571) were recorded in the International Agency for Research
- 183 on Cancer TP53 database (58). All *TP53* pathogenic mutations were found in Chinese patients,
- except c.A1073T (one each in a Chinese and a Caucasian patient) (Supplementary Figure 4). Three of
- the *TP53* mutations, c.C742T, c.C586T, and c.C817T, have been reported in osteosarcoma (39), and
- 186 *TP53* c.C742T has also been identified in low-grade glioma (17) (Supplementary Figure 4).
- 187 Pathogenic mutations in *GJB2* represented the second most frequently mutated CSGs (Figure 1);
- their detection rate was 1.40% (8/571). The c.235delC (rs80338943) mutation, a common pathogenic
- 189 frameshift deletion mutation in East Asian (EAS) populations, has been detected in six Asian
- 190 (Chinese) patients with ESCC (59). Because this mutation has not been detected in other populations,
- rs80338943 may be specific to Chinese or Asian populations.
- 192 Nonsynonymous single-nucleotide variations occupied no less than 50% of pathogenic germline
- 193 mutations in BRCA2, RECQL4, and MUTYH (Supplementary Table 6). In the upstream region, we
- detected a pathogenic splice mutation, *BRCA2* c.-39-1_-39delGA (rs758732038), in a patient, and the
- 195 mutation was reported in ClinVar as likely pathogenic (46). The mutation has also been reported in
- patients with breast cancer and medulloblastoma (60–62). *RECQL4* pathogenic mutations were only
- detected in Asian (Chinese) patients in our study, and *RECQLA* c.C2272T has been reported in
- 198 ovarian cancer/Rothmund–Thomson syndrome. In our study, *MUTYH* c.C1178T (rs36053993) and
- 199 c.C458T (rs762307622) were detected three times (0.53%, or 3/571) and two times (0.35%, or
- 200 2/571), respectively. rs36053993 only detected in Caucasian patients and rs762307622 only detected
- in Asian (Chinese) patients. From gnomAD, rs36053993 in a homozygous state was found in three
- non-Finnish Europeans; this mutation may have been caused by founder events (63,64). Pathogenic mutations in *PMS2* were detected five times in five patients in our study (0.88%), and
- 204 c.2192 2196delAGTTA (rs63750695) was observed in only four patients, who were all African. The
- rs63750695 mutation has also been discovered in Lynch syndrome, colorectal cancer, and ovarian
- 206 carcinoma (65–67); however, it was rare in noncancer gnomAD and ChinaMAP, for which
- frequencies were 1.15×10^{-5} and 0, respectively (Figure 1). rs63750695 is possibly specific to
- 208 African ethnicity in ESCC.
- The total number of pathogenic germline mutations and the frequency of mutations were relatively lower in oncogenes and nonclassified genes compared with TSGs. *TSHR* and *MPL* were oncogenes

- that were mutated in two patients with ESCC; other oncogenes occurred in just one patient.
- 212 *SLC25A13* was one of the nonclassified genes with the most pathogenic mutations.
- 213 We also investigated our pathogenic germline mutations in a previous pan-cancer study (17). Nine
- 214 mutations were spread over 22 samples with diverse cancers (Supplementary Table 9). SLC25A13
- 215 c.852_855delCATA (n = 7), GJB2 c.235delC (n = 7), and PALB2 c.C2257T (n = 2) were the variants
- 216 observed more than once across cancers. We detected multiple susceptibility loci (31/47), also
- 217 identified in previous genome-wide association studies, in our patients with ESCC (Supplementary
- Table 10) (8–16). Of those genes with susceptibility loci, pathogenic mutations *PDE4D* c.T108A and
- *RUNX1* c.61+1delG were found in two patients separately (Supplementary Table 5). We also confirmed from the COSMIC database that 87.3% (137/157) of pathogenic mutations in CSGs had
- nonsilent somatic mutations in the same or a nearby (within five) amino acid position
- 221 nonstient somatic mutations in the same of a nearby (within five) amino acid position
- (Supplementary Table 6). Among 137 mutations, 107 mutations were observed in TSGs, representing
- 223 89.2% (107/120) of all mutations.
- 224 [Insert Table 1 here]

225 **3.3** Pathogenic germline mutations frequency in ESCC cases versus controls

226 To reveal the relationships between highly frequent mutated CSGs and ESCC, we chose the Chinese 227 patients to continue the study, to leverage the most population data and avoid any ethnicity-specific effect. We conducted gene-based association analyses by comparing various germline mutation data 228 229 from individuals with ESCC versus a 1000 Genomes Project EAS population and versus a 230 ChinaMAP population separately (57,68). We also conducted rare variant burden tests on the ESCC 231 individuals and the 1000 Genomes Project EAS population (68). Through the same pathogenicity 232 evaluation pipeline, pathogenic mutations were identified in two public database populations. 233 Analysis of results identified significantly higher pathogenic mutations in Chinese patients with ESCC versus public population databases (including 1000 Genomes Project EAS and ChinaMAP 234 235 data), as reflected by odd ratios (ORs) of pathogenic mutations in TP53 from the Chinese ESCC 236 populations compared with the 1000 Genomes Project EAS populations (OR = 4.26; 95% CI, 1.33-17.91; Fisher's exact test $p = 7.359 \times 10^{-3}$) and compared with the ChinaMAP populations(OR = 237 10.59; 95% CI, 5.21-20.45; Fisher's exact test $p = 1.851 \times 10^{-9}$); in *BRCA2* from the Chinese ESCC 238 239 populations compared with the 1000 Genomes Project EAS populations (OR= infinity; 95% CI, 1.09-240 infinity; Fisher's exact test p = 0.0197) and compared with the ChinaMAP populations (OR = 2.68; 241 95% CI, 0.83-6.75; Fisher's exact test p = 0.0489); and in *RECOL4* from the Chinese ESCC 242 populations compared with the 1000 Genomes Project EAS populations (OR = 7.21; 95% CI, 0.87-243 332.231; Fisher's exact test p = 0.0519) and compared with the ChinaMAP populations (OR = 3.69; 244 95% CI, 1.27-8.81; Fisher's exact test p = 0.0089)(Table 1). Likewise, in the burden analyses (Table 245 1), the numbers of pathogenic mutations from TP53 (14/424, or 3.30%; burden test $p = 3.050 \times 10^{-3}$), 246 *BRCA2* (5/424, or 1.18%; burden test p = 0.015), and *RECOL4* (6/424, or 1.14%; burden test p = 0.015). 247 0.035) in our Chinese ESCC cohort were higher than those observed in the 1000 Genomes Project 248 EAS group.

249 [Insert Figure 2 here]

250 **3.4 Potential double-hit events**

251 To further survey the genetic predisposition of ESCC, we tried to identify potential double-hit events

- in ESCC. First, we identified 49,876 nonsilent mutations (Supplementary Table 3) in protein-coding
- 253 regions from patients with ESCC. (We filtered the somatic mutations that overlapped with our own

- 254 panel of normal datasets and the Exome Aggregation Consortium database.) Then, by integrating
- 255 pathogenic germline mutations and effective somatic mutations (Supplementary Table 8) or allele
- loss SCNVs, we found 84 potential double-hit events (Figure 2). To distinguish hits with germline
- 257 mutations, the double-hit events were classified as germline/somatic double-hit events and
- somatic/somatic double-hit events. We identified 16 potential germline/somatic double-hit events
- 259 (two germline mutations coupled with somatic mutations, and 14 germline mutations accompanied
- with allele loss SCNVs) (Figure 2, Supplementary Table 11 and Supplementary Figures 5, 6) in 16 patients with ESCC, and we identified 68 potential somatic/somatic double-hit events (three somatic
- patients with ESCC, and we identified 68 potential somatic/somatic double-hit events (three somat
 mutations accompanied by allele loss SCNVs and 65 double somatic mutations) (Figure 2.
- mutations accompanied by allele loss SCNVs and 65 double somatic mutations) (Figure 2,
 Supplementary Table 12) in 67 cases. The likelihood of two or more somatic mutations happening on
- the same chromosome was very low (52,69,70). Therefore, we assumed that double somatic
- 265 mutations were likely in the trans position. Briefly, 83 individuals with ESCC possessed potential
- 266 double-hit events, representing 14.5% of the ESCC cohort (Figure 2). Notably, one patient had two
- 267 somatic/somatic double-hit events in different genes.
- 268 GJB2 and TP53 were the top two CSGs that found germline/somatic double-hit events.
- 269 Germline/somatic double-hit events were identified in eight CSGs, including BRCA2, BRCA1,
- 270 MUTYH, CDKN2A, and ATM. The dominant type of germline/somatic double-hit events was a
- 271 germline mutation accompanied by an allele loss SCNV. In the remaining, germline mutations were
- coupled with somatic mutations; these were only discovered in *TP53* and *BRCA1*, possibly because
- SCNVs are relatively abundant in tumors and cover large genome region. In the somatic/somatic
- double-hit events, the *TP53* gene had the highest frequency, and most of the remaining genes had one
- 275 potential double-hit event. Double somatic mutation was the main type of somatic/somatic double-hit
- event (Supplementary Table 12).
- 277 [Insert Figure 3 here]
- 278 When we compared diagnosis ages of patients with different double-hit events, we found that
- 279 patients with germline/somatic double-hit events (with pathogenic germline mutations) had younger
- diagnosis ages (mean age [SD], 54.6 [11.2] years; [range, 36–71 years]) compared with patients in
- the somatic/somatic double-hit events (without pathogenic germline mutations; mean age [SD], 60.6
- 282 [7.8] years; [range, 4–80 years]; t-test p = 0.056; 95% CI, -12.216 to 0.177) (Figure 3). The
- comparison was nonsignificant, maybe it's due to the limited number of samples with double-hit
- events in this comparison. However, the finding was consistent in the study by Knudson (21). Using
 the empirical cumulative distribution function (ecdf) to calculated the expression percentiles of TSGs
- in an ESCC-P006 cancer cohort, two patients with somatic/somatic double-hit events showed low
- expression: one in *TP53* (5.32%) and one in *PTEN* (6.38%) (Supplementary Figure 8) (17). Those
- results support the two-hit hypothesis and suggest that genetic screening in specific TSGs can detect
- 289 patients with germline/somatic double-hit events earlier.
- 290 [Insert Figure 4 here]

291 **3.5 Pathway enrichment**

- 292 To obtain a more comprehensive understanding of pathogenic germline genetic mutations affecting
- 293 pathways, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed
- for multiple gene lists. The Fanconi anemia (FA) pathway was the most significantly enriched in the
- analysis of 75 pathogenically mutated CSGs (Fisher's exact test $p = 6.634 \times 10^{-19}$) (Figure 4A,
- Supplementary Table 7). In addition, 1,226 pathogenic mutated genes and the genes involved in
- 297 germline/somatic double-hit events were significantly enriched in this pathway. The top four

- 298 pathways for CSGs involved in somatic/somatic double-hit events versus for CSGs involved in
- 299 germline/somatic double-hit events differed significantly (Supplementary Figures 7A-D).
- 300 In the tumor-suppressor network, the FA pathway functions to preserve genomic integrity by
- 301 repairing DNA interstrand crosslinks, regulating cytokinesis, and mitigating replication stress
- 302 (71,72). 33 ESCC samples carried pathogenic mutations in 13 CSGs included in the FA pathway
- 303 (Figure 4B). The homologous recombination pathway and the mismatch repair pathway described in
- a previous ESCC project, and associated with cancer susceptibility, were found in our study
- 305 (Supplementary Figure 7A) (19,73–75). Those pathways were also reported in pathway enrichments
- 306 of ovarian cancer and osteosarcoma (39,76). We also interrogated the oncogenic signaling pathways
- 307 upon which our mutated CSGs converged (77). The cell cycle pathway was the most enriched,
- followed by p53 pathway, the phosphatidylinositol 3'-kinase-Akt pathway, and the receptor tyrosine kinases-Ras pathway.

310 4 Discussion

311 We reported the profile of pathogenic germline mutations of a larger ESCC cohort comparing with

- 312 previous studies (17,19). We found 157 pathogenic mutations in CSGs from 143 (25.0%) of 571
- patients with ESCC and identified 84 double-hit events in 83 individuals (14.5%). Double-hit events
- 314 were found in almost all projects in our study except ESCC-P008, which demonstrated that double-
- 315 hit events are relatively common in ESCC. As far as we know, there was no report about pathogenic
- mutations in *GJB2*, *RECQL4*, *MUTYH* and *PMS2* in ESCC, however, they were discovered in our
- study. Overall, *TP53*, *GJB2*, *BRCA2*, *RECQL4*, *MUTYH*, and *PMS2* were highly frequently mutated
 CSGs. Significant pathways were identified for different CSGs with pathogenic mutations; the FA
- 318 CSGs. Significant pathways were identified for different CSGs with pathogenic mutations; the FA 319 pathway appeared to be a primary pathway for cancer predisposition in ESCC. We showed that
- significantly more pathogenic mutations from *TP53*, *BRCA2* and *RECOL4* occurred in patients with
- 321 ESCC than in control cohorts, which indicates that these three CSGs may play vital roles in ESCC.
- 322 Interestingly, *TP53* and *RECQL4* have also been found significantly associated with osteosarcoma
- 323 (39). The relationship with diagnosis age was not significant in our study, but double-hit events may
- 324 be pivotal in ESCC carcinogenesis.
- We found that *TP53* had the highest frequency of pathogenic germline mutations and the most
- double-hit events in CSGs. In our study, 80% (12/15) of germline mutations in *TP53* were located in
- 327 the p53 domain, which functions in DNA binding. This domain contains four conserved regions that
- 328 are enriched for somatic mutation hot spots and are essential for the function of the TP53 protein as a
- transcription factor (78,79). Six of the 12 mutations were discovered in conserved regions.
- 330 Environmental factors and specific DNA sequences drive higher mutation rates, which may explain
- 331 why p53 domain was a hot-spot region (80). Those pathogenic *TP53* mutations may disrupt the p53
- transcriptional pathway, which would enhance tumor progression and metastatic potential (81). The
- 333 US Food and Drug Administration had approved drugs against the pocket in p53 domain (82). These
- drugs provide treatment options to patients with tumors that have mutations in the p53 domain.
- Results of studies in other cancers contrast with our findings about *TP53*. In a renal cell carcinoma
- 336 study, *FH*, instead of *TP53*, harbored the most double-hit events, and *BRCA1* harbored the most in a 337 pan-cancer study(17,22). Previous studies have reported that most double-hit events with *TP53*
- involve a mutation accompanied by LOH (83,84). However, in our research, double somatic
- 339 mutations were the dominant type of double-hit event. It was partially due to the lack of researches
- 340 on *TP53* double somatic mutations before.

- 341 *BRCA2* and *RECQL4* harbored more pathogenic germline mutations in ESCC than in public
- 342 population. *BRCA2* is known for its involvement in breast cancer and ovarian cancer via the
- homologous recombination pathway, which is essential for repairing damaged DNA (85,86). And
- 344 studies have reported *BRCA2* mutations related to ESCC risk in Chinese and Turkmen populations
- (20,87,88). The double-hit events detected in *BRCA2* in our study were germline/somatic double-hit
 events; the germline mutations were accompanied by allele loss SCNVs. These results were distinct
- from those reported in pancreatic acinar-cell carcinomas (89). *RECOL4* is a TSG that encodes
- 348 RECOL4 helicase, which is involved in DNA replication and DNA repair. Germline mutations in
- 349 *RECOL4* can cause Rothmund-Thomson syndrome and sporadic breast cancer (90). Although the
- 350 pathogenic mutations in our ESCC cohort and in the 1000 Genomes EAS group were not
- 351 significantly different (Fisher's exact test p = 0.0519), the difference between them was also
- 352 confirmed by analysis of the ChinaMAP cohort (Fisher's exact test p = 0.0089). Importantly, this is
- the first report, to our knowledge, that illustrates the role of pathogenic mutations in *RECQL4* in
- 354 ESCC.
- 355 The PMS2 protein is a homolog of the PMS1 protein (91) and both of them are components of the
- 356 mismatch repair system. Common polymorphisms of *PMS1* have been positively associated with
- 357 ESCC in an African population (92). This finding, together with the connection between PMS1 and
- 358 PMS2, suggests a possible relationship between *PMS2* and ESCC. Double-hit events of mismatch
- repair genes could result in Lynch syndrome, as described in several studies (70,93), but we did not
- detect double-hit events in *PMS2* in our ESCC cohort. A larger ESCC cohort study might uncover
- double-hit events in *PMS2*, which would strengthen our understanding about ESCC susceptibility.
- 362 The genetic variations in ESCC are complicated. Although not all ESCC samples carried pathogenic
- 363 germline mutations in CSGs, the detection rate of pathogenic mutations was close to that found in
- 364 osteosarcoma (39). Because numerous susceptibility loci reported in genome-wide association
- 365 studies were found in this research, we acknowledge that pathogenic mutations and known
- 366 susceptibility loci may inform a genetic basis of ESCC. Our findings of variants and genes shared
- 367 between ESCC and other cancers suggests that common hereditary factors exist in pan-cancer. Given
- the interplay of common SNPs and pathogenic mutations reported in breast cancer and colorectal
- 369 cancer, the interaction between susceptibility loci and pathogenic mutations in ESCC suggests a need
- 370 for future exploration (94).
- 371 To better understand the genetic factors causing ESCC initiation and development, we confirmed the
- 372 putative germline-somatic interplay by COSMIC proximity match. The results not only support the
- pathogenicity of those germline mutations but also imply a signal functional relevance between
- 374 germline and somatic mutations (76). In addition, we identified potential double-hit events in 83
- 375 patients with ESCC; though the difference was not significant, the patients with germline/somatic
- double-hit events were more likely to be diagnosed at younger ages. It is possible that pathogenic
- 377 mutations confer the earliest genetic hits to TSGs in cells, so a somatic hit alone would cause loss of
- 378 function in TSGs (95). As a result of double-hit events, the cells generate malignancy. Furthermore,
- enriched pathways revealed the process of pathogenic mutations that affect ESCC tumorigenesis and
- development. In patients without pathogenic mutations or double-hit events, limited CSG sets,
 potential alternations in methylations of a promoter region, germline CNVs, and gene-environmental
- 382 or gene-lifestyle interactions are possible explanations for ESCC development.
- 383 Despite our findings about the genetic characterization of and double-hit events in ESCC, we still 384 acknowledge limitations to our study. The first is our inability to obtain detailed clinical information
- acknowledge limitations to our study. The first is our inability to obtain detailed clinical information
- because of limited access to public databases. Second, merging different data, such as WGS and

- 386 WES, may induce biases in cohort-wide variant processing. Third, directly adopting variants from
- 387 different sources may influence comparisons, because the different sources applied distinct platforms
- and variant detection pipelines. Fourth, our sample size was not large enough for statistical tests,
- 389 especially for individual variants.
- In sum, we report that approximately 25.0% of patients with ESCC harbored at least one pathogenic
 germline mutation in CSGs, and approximately 14.5% of ESCC cases could be explained by a two hit hypothesis. Significantly enriched pathways also validated the significance of those pathogenic
- 393 mutations. Myriad genome variations occur in patients; our findings represent, to our knowledge, the
- 394 largest discovery of rare, germline predisposition mutations in ESCC so far. These results strengthen
- the understanding about genetic factors involved in ESCC and will help improve prevention, early
- detection, and risk management of ESCC for patients. We acknowledge the shortcomings in the
- analytical methods and the data sources used. Additional studies are needed to improve our
- 398 observations and results.

399 5 Data availability statement

- 400 The raw data of this project can be found in the Sequence Read Archive hosted by the National
- 401 Center for Biotechnology Information under accession numbers PRJNA315775, PRJNA399748,
- 402 PRJNA401209, PRJNA230271, PRJNA317404, SRA112617 and SRP034680 and in the European
- 403 Genome-Phenome Archive under accession number EGAD00001000845. The whole-exome
- 404 sequencing data of esophageal squamous cell cancer samples from The Cancer Genome Atlas are
- 405 available from the National Cancer Institute Genomic Data Commons
- 406 (https://portal.gdc.cancer.gov/). All relevant datasets for this study are available from the authors.

407 6 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial
 relationships that could be construed as a potential conflict of interest.

410 **7** Author Contributions

- 411 LL and BZ: conceptualization. BZ: writing manuscript and performing analysis. PD, XS and XH:
- 412 providing help in analysis. BZ, LL, XH and PD: collected the data from published literature or
- 413 database. P H revised the manuscript. LL and XF supervised and supported this project.
- 414 **8 Funding**
- 415 No funding.

416 9 Acknowledgments

- 417 This study makes use of data generated by the Molecular Oncology Laboratory of Prof. Qimin Zhan,
- 418 the Translational Medicine Research Center, Shanxi Medical University of Prof. Yongping Cui, the
- 419 Department of Radiation Oncology, Fudan University Shanghai Cancer Center of Prof. Kuaile Zhao,
- 420 the Department of Bioinformatics and Computational Biology, The University of Texas MD
- 421 Anderson Cancer Center of Prof. Han Liang, The Lineberger Comprehensive Cancer Center,
- 422 University of North Carolina School of Medicine, Prof. Norman E. Sharpless, the Institute of Clinical
- 423 Pathology, Shantou University Medical College, Prof. Min Su, the Cedars-Sinai Medical Center,
- 424 UCLA School of Medicine, Prof. H. Phillip Koeffler and Prof. Jie He of Cancer Institute and

425 Hospital Chinese Academy of Medical Sciences. We also acknowledge other Professors for sharing

- 426 the fastq data, The National Center for Biotechnology Information, The European Genome-phenome
- 427 Archive, The Cancer Genome Atlas for sharing the esophageal squamous cell cancer data.
- The last but not the least, I want to thanks to my wife Panhong Liu, without her support, without my scientific research.

430 **10 References**

- Brown J, Stepien AJ, Willem P. Landscape of copy number aberrations in esophageal
 squamous cell carcinoma from a high endemic region of South Africa. *BMC cancer* (2020)
 20:281. doi:10.1186/s12885-020-06788-3
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer
 statistics in China, 2015. *CA: A Cancer Journal for Clinicians* (2016) 66:115–132.
 doi:10.3322/caac.21338
- 437 3. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB,
 438 Mayne ST, Dubrow R, Rotterdam H, et al. Population attributable risks of esophageal and
 439 gastric cancers. *Journal of the National Cancer Institute* (2003) 95:1404–1413.
 440 doi:10.1093/jnci/djg047
- 441 4. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang JJ, Xu L, Zhou Y, et al.
 442 Identification of genomic alterations in oesophageal squamous cell cancer. *Nature* (2014)
 443 508:91–95. doi:10.1038/nature13176
- 444 5. Gao YB, Chen ZL, Li JG, Hu X da, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et
 445 al. Genetic landscape of esophageal squamous cell carcinoma. *Nature Genetics* (2014)
 446 46:1097–1102. doi:10.1038/ng.3076
- 6. Chen XX, Zhong Q, Liu Y, Yan SM, Chen ZH, Jin SZ, Xia TL, Li RY, Zhou AJ, Su Z, et al.
 Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by
 multi-region whole-exome sequencing. *Nature Communications* (2017) 8:
 doi:10.1038/s41467-017-00650-0
- 451 7. Liu X, Zhang M, Ying S, Zhang C, Lin R, Zheng J, Zhang G, Tian D, Guo Y, Du C, et al.
 452 Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma.
 453 *Gastroenterology* (2017) 153:166–177. doi:10.1053/j.gastro.2017.03.033
- Kamatani Y, Takahashi A, Usami M, Hosono N, Kawaguchi T, Tsunoda T, Kamatani
 N, Kubo M, Nakamura Y, et al. Functional Variants in ADH1B and ALDH2 Coupled With
 Alcohol and Smoking Synergistically Enhance Esophageal Cancer Risk. *Gastroenterology* (2009) 137:1768–1775. doi:10.1053/j.gastro.2009.07.070
- 458
 9. Wang LD, Zhou FY, Li XMXCXM, Sun LD, Song X, Jin Y, Li JLM, Kong GQ, Qi H, Cui J,
 459 et al. Genome-wide association study of esophageal squamous cell carcinoma in chinese
 460 subjects identifies a susceptibility locus at PLCE1. *Nature Genetics* (2010) 42:759–765.
 461 doi:10.1038/ng.648

462 463 464	10.	Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, Liu Z, Zhan Q, Liu Y, Yu D, et al. Genome- wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. <i>Nature Genetics</i> (2011) 43 :679–684. doi:10.1038/ng.849
465 466 467 468	11.	Wu C, Kraft P, Zhai K, Chang J, Wang Z, Li Y, Hu Z, He Z, Jia W, Abnet CC, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. <i>Nature Genetics</i> (2012) 44 :1090–1097. doi:10.1038/ng.2411
469 470 471 472	12.	Wu C, Wang Z, Song X, Feng XS, Abnet CC, He J, Hu N, Zuo XB, Tan W, Zhan Q, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. <i>Nature Genetics</i> (2014) 46 :1001–1006. doi:10.1038/ng.3064
473 474 475 476	13.	Lin D, Wu C, Li D, Jia W, Hu Z, Zhou Y, Yu D, Tong T, Wang M, Lin D, et al. Genome- wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. <i>Nature Genetics</i> (2013) 45 :632–638. doi:10.1038/ng.2638
477 478 479 480	14.	Chang J, Zhong R, Tian J, Li J, Zhai K, Ke J, Lou J, Chen W, Zhu B, Shen N, et al. Exome- wide analyses identify low-frequency variant in CYP26B1 and additional coding variants associated with esophageal squamous cell carcinoma. <i>Nature Genetics</i> (2018) 50 :338–343. doi:10.1038/s41588-018-0045-8
481 482 483	15.	Hu JL, Hu XL, Lu CX, Chen XJ, Fu L, Han Q, Cang SD. Variants in the 3'-untranslated region of CUL3 is associated with risk of esophageal squamous cell carcinoma. <i>Journal of Cancer</i> (2018) 9 :3647–3650. doi:10.7150/jca.27052
484 485 486 487	16.	Suo C, Yang Y, Yuan Z, Zhang T, Yang X, Qing T, Gao P, Shi L, Fan M, Cheng H, et al. Alcohol Intake Interacts with Functional Genetic Polymorphisms of Aldehyde Dehydrogenase (ALDH2) and Alcohol Dehydrogenase (ADH) to Increase Esophageal Squamous Cell Cancer Risk. <i>Journal of Thoracic Oncology</i> (2019) 14 :712–725. doi:10.1016/j.jtho.2018.12.023
488 489 490	17.	Huang K lin, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> (2018) 173 :355-370.e14. doi:10.1016/j.cell.2018.03.039
491 492 493	18.	Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, et al. The landscape of genomic alterations across childhood cancers. <i>Nature</i> (2018) 555 :321–327. doi:10.1038/nature25480
494 495 496	19.	Deng J, Weng X, Ye J, Zhou D, Liu Y, Zhao K. Identification of the germline mutation profile in esophageal squamous cell carcinoma by whole exome sequencing. <i>Frontiers in Genetics</i> (2019) 10 :1–10. doi:10.3389/fgene.2019.00047
497 498 499 500	20.	Ko JMY, Ning L, Zhao XK, Chai AWY, Lei LC, Choi SSA, Tao L, Law S, Kwong A, Lee NPY, et al. BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese. <i>International Journal of Cancer</i> (2020) 146 :1042–1051. doi:10.1002/ijc.32619

- 501 21. Knudson AG. Two genetic hits (more or less) to cancer. *Nature Reviews Cancer* (2001)
 502 1:157–162. doi:10.1038/35101031
- 503 22. Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-birsoy O, Huang K, Redzematovic A,
 504 Coskey DT, Stewart C, Pradhan N, et al. Prevalence of Germline Mutations in Cancer
 505 Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. (2018) 10065:
 506 doi:10.1001/jamaoncol.2018.1986
- 507 23. Park S, Supek F, Lehner B. Systematic discovery of germline cancer predisposition genes
 508 through the identification of somatic second hits. *Nature Communications* (2018) 9:
 509 doi:10.1038/s41467-018-04900-7
- Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding
 LW, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. *Nature Genetics* (2014) 46:467–473. doi:10.1038/ng.2935
- 513 25. Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P, Wang JJJJ, Li YY, Chen W, Song B,
 514 et al. Genomic analyses reveal mutational signatures and frequently altered genes in
 515 esophageal squamous cell carcinoma. *American Journal of Human Genetics* (2015) 96:597–
 516 611. doi:10.1016/j.ajhg.2015.02.017
- 517 26. Hao JJ, Lin DC, Dinh HQ, Mayakonda A, Jiang YY, Chang C, Jiang Y, Lu CC, Shi ZZ, Xu
 518 X, et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal
 519 squamous cell carcinoma. *Nature Genetics* (2016) 48:1500–1507. doi:10.1038/ng.3683
- Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, Patel N, Mlombe YB,
 Mulima G, Liomba NG, et al. Subtyping sub-Saharan esophageal squamous cell carcinoma by
 comprehensive molecular analysis. *JCI Insight* (2016) 1:1–11. doi:10.1172/jci.insight.88755
- 523 28. Deng J, Chen H, Zhou D, Zhang J, Chen Y, Liu Q, Ai D, Zhu H, Chu L, Ren W, et al.
 524 Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and
 525 Caucasian patient populations. *Nature Communications* (2017) 8:1–9. doi:10.1038/s41467526 017-01730-x
- 527 29. Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, Shih J, Pedamallu
 528 CS, Cibulskis C, Dunford A, et al. Integrated genomic characterization of oesophageal
 529 carcinoma. *Nature* (2017) 541:169–174. doi:10.1038/nature20805
- 30. Ajay SS, Parker SCJ, Abaan HO, Fuentes Fajardo K v., Margulies EH. Accurate and
 comprehensive sequencing of personal genomes. *Genome Research* (2011) 21:1498–1505.
 doi:10.1101/gr.123638.111
- 533 31. Chen Y, Chen Y, Shi C, Huang Z, Zhang Y. SOAPnuke : A MapReduce Acceleration
 534 supported Software for integrated Quality Control and Preprocessing of High-Throughput
 535 Sequencing Data. *GigaScience* (2018) 7:gix120. doi:10.1093/gigascience/gix120/4689118
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K,
 Altshuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: A MapReduce framework
 for analyzing next-generation DNA sequencing data. *Genome Research* (2010) 20:1297–1303.
 doi:10.1101/gr.107524.110

- 540 33. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.
 541 *Bioinformatics* (2010) 26:589–595. doi:10.1093/bioinformatics/btp698
- McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flicek P, Cunningham F.
 The Ensembl Variant Effect Predictor. *Genome Biology* (2016) 17:1–14. doi:10.1186/s13059016-0974-4
- 54535.Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ. Oncotator : Cancer Variant546Annotation Tool. *Human Mutation* (2015) **36**:E2423–E2429. doi:10.1002/humu.22771
- Mayrhofer M, DiLorenzo S, Isaksson A. Patchwork: Allele-specific copy number analysis of
 whole-genome sequenced tumor tissue. *Genome Biology* (2013) 14:R24. doi:10.1186/gb2013-14-3-r24
- Shen R, Seshan VE. FACETS: Allele-specific copy number and clonal heterogeneity
 analysis tool for high-throughput DNA sequencing. *Nucleic Acids Research* (2016) 44:1–9.
 doi:10.1093/nar/gkw520
- 553 38. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson
 554 E, Ponting L, et al. COSMIC: Somatic cancer genetics at high-resolution. *Nucleic Acids*555 *Research* (2017) 45:D777–D783. doi:10.1093/nar/gkw1121
- Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector LG,
 Morton LM, Karyadi D, et al. Frequency of pathogenic germline variants in cancersusceptibility genes in patients with osteosarcoma. *JAMA Oncology* (2020) 6:724–734.
 doi:10.1001/jamaoncol.2020.0197
- 560 40. Zhao M, Sun J, Zhao Z. TSGene: A web resource for tumor suppressor genes. *Nucleic Acids* 561 *Research* (2013) 41:970–976. doi:10.1093/nar/gks937
- 562 41. Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. TSGene 2.0: An updated literature-based
 563 knowledgebase for Tumor Suppressor Genes. *Nucleic Acids Research* (2016) 44:D1023–
 564 D1031. doi:10.1093/nar/gkv1268
- Liu Y, Sun J, Zhao M. ONGene: A literature-based database for human oncogenes. *Journal* of Genetics and Genomics (2017) 44:119–121. doi:10.1016/j.jgg.2016.12.004
- 567 43. Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG568 AMP Guidelines. American Journal of Human Genetics (2017) 100:267–280.
 569 doi:10.1016/j.ajhg.2017.01.004
- 44. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E,
 Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint
 consensus recommendation of the American College of Medical Genetics and Genomics and
 the Association for Molecular Pathology. *Genetics in Medicine* (2015) 17:405–423.
 doi:10.1038/gim.2015.30
- 575 45. Stenson PD, Mort M, Ball E v., Evans K, Hayden M, Heywood S, Hussain M, Phillips AD,
 576 Cooper DN. The Human Gene Mutation Database: towards a comprehensive repository of

577 578		inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. <i>Human Genetics</i> (2017) 136 :665–677. doi:10.1007/s00439-017-1779-6
579 580 581	46.	Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: Improving access to variant interpretations and supporting evidence. <i>Nucleic Acids Research</i> (2018) 46 :D1062–D1067. doi:10.1093/nar/gkx1153
582 583 584	47.	Lek M, Karczewski KJ, Minikel E v., Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. Analysis of protein-coding genetic variation in 60,706 humans. <i>Nature</i> (2016) 536 :285–291. doi:10.1038/nature19057
585 586 587	48.	Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, Newburger D, Dijamco J, Nguyen N, Afshar PT, et al. A universal snp and small-indel variant caller using deep neural networks. <i>Nature Biotechnology</i> (2018) 36 :983. doi:10.1038/nbt.4235
588 589 590	49.	Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. <i>Nature Protocols</i> (2009) 4 :1073–1082. doi:10.1038/nprot.2009.86
591 592 593	50.	Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. <i>Nature Methods</i> (2010) 7 :248–249. doi:10.1038/nmeth0410-248
594 595 596	51.	Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: Predicting the deleteriousness of variants throughout the human genome. <i>Nucleic Acids Research</i> (2019) 47 :D886–D894. doi:10.1093/nar/gky1016
597 598 599 600	52.	Geurts-Giele WRR, Leenen CHM, Dubbink HJ, Meijssen IC, Post E, Sleddens HFBM, Kuipers EJ, Goverde A, van den Ouweland AMW, van Lier MGF, et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. <i>Journal of Pathology</i> (2014) 234 :548–559. doi:10.1002/path.4419
601 602 603 604	53.	Cox C, Bignell G, Greenman C, Stabenau A, Warren W, Stephens P, Davies H, Watt S, Teague J, Edkins S, et al. A survey of homozygous deletions in human cancer genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> (2005) 102 :4542–4547. doi:10.1073/pnas.0408593102
605 606 607	54.	Ryland GL, Doyle MA, Goode D, Boyle SE, Choong DYH, Rowley SM, Li J, Bowtell DD, Tothill RW, Campbell IG, et al. Loss of heterozygosity: What is it good for? <i>BMC Medical Genomics</i> (2015) 8 :1–12. doi:10.1186/s12920-015-0123-z
608 609 610	55.	Robinson JT, Thorvaldsdóttir H, Wenger AM, Zehir A, Mesirov JP. Variant review with the integrative genomics viewer. <i>Cancer Research</i> (2017) 77 :e31–e34. doi:10.1158/0008-5472.CAN-17-0337
611 612 613	56.	Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the combined effect of rare and common variants. <i>American Journal of Human Genetics</i> (2013) 92 :841–853. doi:10.1016/j.ajhg.2013.04.015

- 614 57. Cao Y, Li L, Xu M, Feng Z, Sun X, Lu J, Xu Y, Du P, Wang T, Hu R, et al. The ChinaMAP
 615 analytics of deep whole genome sequences in 10,588 individuals. *Cell Research* (2020)
 616 doi:10.1038/s41422-020-0322-9
- 617 58. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53
 618 database: New online mutation analysis and recommendations to users. *Human Mutation*619 (2002) 19:607–614. doi:10.1002/humu.10081
- 59. Dzhemileva LU, Barashkov NA, Posukh OL, Khusainova RI, Akhmetova VL, Kutuev IA,
 621 Gilyazova IR, Tadinova VN, Fedorova SA, Khidiyatova IM, et al. Carrier frequency of GJB2
 622 gene mutations c.35delG, c.235delC and c.167delT among the populations of Eurasia. *Journal*623 of Human Genetics (2010) 55:749–754. doi:10.1038/jhg.2010.101
- 624 60. Kwong A, Shin VY, Ho JCW, Kang E, Nakamura S, Teo SH, Lee ASG, Sng JH, Ginsburg
 625 OM, Kurian AW, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious
 626 mutations in breast cancer in Asian countries. *Journal of Medical Genetics* (2016) 53:15–23.
 627 doi:10.1136/jmedgenet-2015-103132
- 628 61. Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB,
 629 Brugières L, Jones DTW, Pajtler KW, et al. Spectrum and prevalence of genetic predisposition
 630 in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial
 631 cohort. *The Lancet Oncology* (2018) **19**:785–798. doi:10.1016/S1470-2045(18)30242-0
- 632 62. Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, Lee DSC, Lee SY, Yoon SY,
 633 Lim J, et al. Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of
 634 Asian patients with breast cancer and healthy controls from Malaysia. *Journal of Medical*635 *Genetics* (2018) 55:97–103. doi:10.1136/jmedgenet-2017-104947
- 636 63. Aretz S, Tricarico R, Papi L, Spier I, Pin E, Horpaopan S, Cordisco EL, Pedroni M, Stienen
 637 D, Gentile A, et al. MUTYH-associated polyposis (MAP): Evidence for the origin of the
 638 common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. *European*639 *Journal of Human Genetics* (2014) 22:923–929. doi:10.1038/ejhg.2012.309
- 640 64. Taki K, Sato Y, Nomura S, Ashihara Y, Kita M, Tajima I, Sugano K, Arai M. Mutation
 641 analysis of MUTYH in Japanese colorectal adenomatous polyposis patients. *Familial Cancer*642 (2016) 15:261–265. doi:10.1007/s10689-015-9857-1
- 643 65. Klift HM van der, Tops ÃCMJ, Bik EC, Boogaard MW, Borgstein A, Hansson KBM,
 644 Ausems MGEM, Garcia EG, Green A, Hes FJ, et al. Quantification of Sequence Exchange
 645 Events between PMS2 and PMS2CL Provides a Basis for Improved Mutation Scanning of
 646 Lynch Syndrome Patients. *Human Mutation* (2010) **31**:578–587. doi:10.1002/humu.21229
- 647 66. Zhang P, Kitchen-Smith I, Xiong L, Stracquadanio G, Brown K, Richter P, Wallace M, Bond
 648 E, Sahgal N, Moore S, et al. Germline and somatic genetic variants in the p53 pathway interact
 649 to affect cancer risk, progression and drug response. *bioRxiv* (2019)835918.
 650 doi:10.1101/835918
- 651 67. Staninova-Stojovska M, Matevska-Geskovska N, Panovski M, Angelovska B, Mitrevski N,
 652 Ristevski M, Jovanovic R, Dimovski A. Molecular Basis of Inherited Colorectal Carcinomas

653 in the Macedonian Population: An Update. Balkan J Med Genet (2019) 22:5–16. 654 doi:10.2478/bjmg-2019-0025 655 68. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, Clark AG, 656 Donnelly P, Eichler EE, Flicek P, et al. A global reference for human genetic variation. Nature 657 (2015) 526:68-74. doi:10.1038/nature15393 69. 658 Boland CR, Goel A. Microsatellite Instability in Colorectal Cancer. Gastroenterology (2010) 659 138:2073-2087.e3. doi:10.1053/j.gastro.2009.12.064 660 70. Sourrouille I, Coulet F, Lefevre JH, Colas C, Eyries M, Svrcek M, Bardier-Dupas A, Parc Y, 661 Soubrier F. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. 662 Familial Cancer (2013) 12:27-33. doi:10.1007/s10689-012-9568-9 Ceccaldi R, Sarangi P, D'Andrea AD. The Fanconi anaemia pathway: new players and new 663 71. 664 functions. Nature reviews Molecular cell biology (2016) 17:337. doi:10.1038/nrm.2016.48 665 72. Joshi Niraj, Anniina Färkkilä, D'Andrea AD. The Fanconi Anemia Pathway in Cancer. Annu 666 Rev Cancer Biol (2019) 3:457-478. doi:10.1016/j.physbeh.2017.03.040 73. Hsieh P, Yamane K. DNA mismatch repair: Molecular mechanism, cancer, and ageing. Mech 667 Ageing Dev (2008) **129**:391–407. doi:10.1016/j.mad.2008.02.012 668 669 74. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Research (2008) 18:85-98. doi:10.1038/cr.2007.115 670 75. 671 Li X, Heyer W-D. Homologous recombination in DNA reapir and DNA tolerance. Cell Research (2008) 18:99-113. doi:10.1038/cr.2008.1 672 76. 673 Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MDM, Wendl MC, Zhang Q, 674 Koboldt DC, Xie M, Kandoth C, et al. Integrated analysis of germline and somatic variants in 675 ovarian cancer. Nature Communications (2014) 5:1–14. doi:10.1038/ncomms4156 77. 676 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, 677 Kantheti HS, Saghafinia S, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. 678 Cell (2018) 173:321-337.e10. doi:10.1016/j.cell.2018.03.035 679 78. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of 53 contains the four 680 conserved regions the major mutation hot spots. Genes & development (1993) 7:2556-2564. 79. 681 Harms KL, Chen X. The functional domains in p53 family proteins exhibit both common and 682 distinct properties. Cell Death and Differentiation (2006) 13:890-897. 683 doi:10.1038/sj.cdd.4401904 684 80. Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death and Differentiation (2018) 25:154–160. 685 686 doi:10.1038/cdd.2017.180 687 81. Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. Frontiers in Oncology (2015) 5:1-13. doi:10.3389/fonc.2015.00288 688

689 690 691	82.	Pradhan MR, Siau JW, Kannan S, Nguyen MN, Ouaray Z, Kwoh CK, Lane DP, Ghadessy F, Verma S. Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket. <i>Nucleic Acids Research</i> (2019) 47 :1637–1652. doi:10.1093/nar/gky1314
692 693 694	83.	Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. <i>Nature Genetics</i> (2002) 32 :355–357. doi:10.1038/ng1013
695 696 697	84.	Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan CD, Gao J, Spitzer B, Bosbach B, Kastenhuber ER, Baslan T, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. <i>Nature</i> (2016) 531 :471–475. doi:10.1038/nature17157
698 699 700	85.	Buisson R, Dion-Côté A-M, Coulombe Y, Launay H. Cooperation of breast cancer proteins PALB2 and piccolo BRAC2 in stimulating homologous recombination. <i>Nature structural & molecular biology</i> (2010) 17 :1247–1254. doi:10.1038/nsmb.1915
701 702 703 704	86.	Girardi F, Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, Henderson A, Donaldson A, Murray A, Brewer C, et al. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. <i>Genetics in Medicine</i> (2018) 20 :1575–1582. doi:10.1038/gim.2018.44
705 706 707	87.	Hu N, Wang C, Han XY, He LJ, Tang ZZ, Giffen C, Emmert-Buck MR, Goldstein AM, Taylor PR. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. <i>Oncogene</i> (2004) 23 :852–858. doi:10.1038/sj.onc.1207150
708 709 710 711	88.	Akbari MR, Malekzadeh R, Nasrollahzadeh D, Amanian D, Islami F, Li S, Zandvakili I, Shakeri R, Sotoudeh M, Aghcheli K, et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. <i>Oncogene</i> (2008) 27 :1290–1296. doi:10.1038/sj.onc.1210739
712 713 714 715	89.	Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, et al. Germline Brca2 Heterozygosity Promotes KrasG12D -Driven carcinogenesis in a murine model of familial pancreatic cancer. <i>Cancer Cell</i> (2010) 18 :499–509. doi:10.1016/j.ccr.2010.10.015
716 717 718	90.	Arora A, Agarwal D, Abdel-Fatah TMA, Lu H, Croteau DL, Moseley P, Aleskandarany MA, Green AR, Ball G, Rakha EA, et al. RECQL4 helicase has oncogenic potential in sporadic breast cancers. <i>Journal of Pathology</i> (2016) 238 :495–501. doi:10.1002/path.4681
719 720	91.	Zhao L. Mismatch repair protein expression in patients with stage II and III sporadic colorectal cancer. <i>Oncology Letters</i> (2018) 15 :8053–8061. doi:10.3892/ol.2018.8337
721 722 723	92.	Vogelsang M, Wang Y, Veber N, Mwapagha LM, Parker MI. The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. <i>PLoS ONE</i> (2012) 7 :1–10. doi:10.1371/journal.pone.0036962
724 725 726 727	93.	Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de La Chapelle A, Pritchard CC. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. <i>Gastroenterology</i> (2014) 147 :1308-1316.e1. doi:10.1053/j.gastro.2014.08.041

Fahed AC, Wang M, Homburger JR, Patel AP, Bick AG, Neben CL, Lai C, Brockman D,
Philippakis A, Ellinor PT, et al. Polygenic background modifies penetrance of monogenic
variants for tier 1 genomic conditions. *Nature Communications* (2020) 11:1–9.
doi:10.1038/s41467-020-17374-3

- Werness BA, Parvatiyar P, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, OakleyGirvan I, DiCioccio RA, Wiest J, Tsukada Y, Ponder BAJ, et al. Ovarian carcinoma in situ
 with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. *Journal of the National Cancer Institute* (2000) **92**:1088–1091. doi:10.1093/jnci/92.13.1088
- 736
- 737

738 **11 Figure Legends**

Figure 1. The frequency and distribution of cancer susceptibility genes (CSGs) with more than one pathogenic/likely pathogenic germline mutation detected in patients with esophageal squamous cell cancer (ESCC). Only tumor suppressor genes with more than five mutations are shown. Upper bars represent the cumulative mutation numbers of each sample. Bottom bars represent the clinical information (race, gender, age, and survival/death) about the patients. The left table presents the frequency of mutations shown in the noncancer Genome Aggregation Database (gnomAD) and the China Metabolic Analytics Project (ChinaMAP) database. Right bars represent the mutation counts.

The classification of the CSG is next to the mutation name (gene name + reference SNP number or

747 gene name + chromosome position + nucleotide change).

748 **Figure 2.** The distribution of pathogenic/likely pathogenic germline mutations, somatic mutations,

and allele loss somatic copy number variations (SCNVs) in esophageal squamous cell cancer (ESCC)

cases with potential double-hit events. Upper bars represent the clinical information (age and race)

about those patients. Squares represent somatic mutations, triangles represent germline mutations,

and circles represent allele loss SCNVs.

Figure 3. The two types of double-hit events. (A) The paradigm of double-hit events. (B) The

- correlation between age and double-hit event type in esophageal squamous cell cancer (ESCC) cases.
 The position of line is the median age, and the position of rhombus is the mean age in specific ESCC
- cohorts. The digits in the boxes are the numbers of ESCC cases in each category.

757 **Figure 4.** Significantly enriched pathways and networks in esophageal squamous cell cancer

- 758 (ESCC). (A) The network composed of genes involved in the top 10 pathways in the Kyoto
- 759 Encyclopedia of Genes and Genomes pathway enrichment. The red dots represent genes, and the blue
- circles represent pathways. The larger the area, the higher the degree of enrichment. The different
- 761 lines represent various categories of pathways; green lines indicate genetic information processing,
- and purple lines indicate human disease. Solid-line rectangles and solid rectangles in blue, red, and
- yellow represent various gene classifications. (**B**) The x axis represents cancer susceptibility genes
- mutated in the Fanconi anemia pathway; the y axis represents the number of patients affected in our
- 765 cohort. Red font: tumor-suppressor genes.
- Table 1. Significance of *TP53*, *BRCA2*, and *RECQL4* pathogenic or likely pathogenic variants for
 ESCC risk in Chinese patients

	Chinese ESCC cohort(n=424)		1000 Genomes					ChinaMAP			
C			EAS(n=504)					(n=10,558) ²			
Gene	$P_{\rm burden}$	Cases ¹	Controls	p ³	OR	95%CI	_	Controls	n	OD	95%CI
		(n = 424)	(n = 504)	P				(n = 10,558)	P	OR	95%CI

TP53	$3.050\times 10^{\cdot3}$	14 (3.30%)	4 (0.79%)	7.359×10^{-3}	4.26	1.33 to 17.91	34 (0.32%)	1.851×10^{-9}	10.59	5.21 to 20.45
BRCA2	0.015	5 (1.18%)	0 (0%)	0.0197	Inf	1.09 to Inf	47 (0.44%)	0.0489	2.68	0.83 to 6.75
RECQL4	0.035	6 (1.14%)	1 (0.20%)	0.0519	7.21	0.87 to 332.23	41 (0.39%)	0.0089	3.69	1.27 to 8.81

Abbreviations: ChinaMAP, China Metabolic Analytics Project; EAS, East Asian; ESCC, esophageal squamous cell cancer; OR, odd ratio; CI, confidence interval; Inf, infinity.


- ¹Mutation annotation are based on *TP53* transcript: NM_001126112, *BRCA2* transcript: NM_000059
 and *RECQL4* transcript: NM_004260.
- ²ChinaMAP, *TP53*, *BRCA2*, and *RECQL4* variants were exported from http://www.mbiobank.com/
 on June 2, 2020.
- ³Fisher exact test.

- 1847.000		
non-cancer gnomAD		0-
0.0002	0.000803	
7.46E-05	-	
-	-	
-	-	
-	-	
1.12E-05	1-	
-	-	
-	-	
-	-	
1.12E-05	-	100
-	9.44E-05	
-	-	
-		1111
	-	1111
0.0061	0.008359	
	0.000309	
0.0002	-	
3.30E-05	4 7 25 .05	
6.58E-05	4.72E-05	
8.31E-05	4.72E-05	
-	-	
0.0003	0.000803	
-	9.44E-05	
3.28E-05	-	
0.0007	0.000189	
0.0001	-	
-	-	
-	-	
0.0051	0.000236	
2.92E-05	4.72E-05	
0.0008	0.000189	
1.15E-05	-	
-	-	
-	-	1111
-	0.000142	
0.0006	-	1111
-	-	1111
0.0019	0.001606	1111
0.0054	0.004392	1111
-	-	1111
3.27E-05	-	100
-		1111
0.0005	0.000283	
0.0005	4.72E-05	
- 0.0042	4.72E-05	
0.0042		
-	4 725 05	
2.92E-05	4.72E-05	
0.0006	0.000708	
0.0007	-	
7.56E-05	0.000283	
0.0011	4.72E-05	
-	-	


Туре


Missense

Nonsense



20








The germline/somatic double-hit events







*


Х


(B)

The somatic/somatic double-hit events









Fanconi anemia pathway

(B